Stocks Health care DFTX
NASDAQ · Health careDefinium Therapeutics, Inc. (DFTX)
It posted a net loss of $353.8M. At June 30, 2026 it held $655.3M in cash against $36.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Definium Therapeutics, Inc. does
Definium Therapeutics, Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NASDAQ under the ticker DFTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$183.8M | -$2.06 | n/a |
| 2024 | n/a | -$108.7M | -$1.54 | n/a |
| 2023 | n/a | -$95.7M | -$2.44 | n/a |
| 2022 | n/a | -$56.8M | -$1.84 | n/a |
| 2021 | n/a | -$93M | -$3.40 | n/a |
| 2021 | n/a | -$33.9M | -$1.92 | n/a |
Latest SEC filings
What Definium Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- September 8, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 24, 2026
- June 24, 2026
- June 22, 2026
Questions about DFTX
What does Definium Therapeutics, Inc. do?
Definium Therapeutics, Inc. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NASDAQ under the ticker DFTX.
Is Definium Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $353.8M.
When did Definium Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the planned insider sale from September 25, 2026.
Similar companies
Follow DFTX
Get an email when Definium Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow DFTX: get an email when it filesWhere the numbers come from
Financial figures are the values Definium Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.